克立硼罗杂质 | 906673-42-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 克立硼罗杂质
• 英文名称: 5-(3-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
• 英文别名: Crisaborole m-Isomer；3-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
• CAS: 906673-42-5
• 化学式: C₁₄H₁₀BNO₃
• 分子量: 251.049
• InChiKey: RUQIPEQILCQEGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  62.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 克立硼罗杂质
  参考文献：
  名称：

  Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

  摘要：

  A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.007

文献信息

• Compounds for the Treatment of Periodontal Disease
  申请人：Sanders Virginia

  公开号：US20070286822A1

  公开（公告）日：2007-12-13

  Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.

  提供了在牙周病治疗中有用的化合物、组合物和方法。
• Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
  作者：Tsutomu Akama、Stephen J. Baker、Yong-Kang Zhang、Vincent Hernandez、Huchen Zhou、Virginia Sanders、Yvonne Freund、Richard Kimura、Kirk R. Maples、Jacob J. Plattner

  DOI：10.1016/j.bmcl.2009.03.007

  日期：2009.4

  A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis. (C) 2009 Elsevier Ltd. All rights reserved.